# Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

> **NCT02857920** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fuda Cancer Hospital, Guangzhou** · enrollment: 45 (actual)

## Conditions studied

- Malignant Solid Tumour

## Interventions

- **DRUG:** Bevacizumab
- **BIOLOGICAL:** NK immunotherapy

## Key facts

- **NCT ID:** NCT02857920
- **Lead sponsor:** Fuda Cancer Hospital, Guangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-01
- **Primary completion:** 2017-08-01
- **Final completion:** 2019-08-01
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2020-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02857920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02857920, "Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02857920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*